Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 1, 2021* This combination vaccine may simplify execution and reduce shots needed to complete CDC's recommended child and adolescent immunization schedule
-
May 27, 2021If approved, teplizumab will be the first disease-modifying therapy in T1D
-
May 27, 2021-- FDA Advisory Committee to Review Biologics License Application for PRV-031 for the Delay of Clinical Type 1 Diabetes --
-
May 19, 2021Early clinical data for investigational oral selective estrogen receptor (SERD), amcenestrant, show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancer
-
May 19, 2021- Amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), achieved an objective response rate of 34% and a clinical benefit rate of 74% in Phase 1 study (AMEERA-1) in combination with palbociclib
-
May 17, 2021- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patients
-
May 12, 2021Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy
-
May 6, 2021Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research* Projects led by collaborating researchers from the two organizations will focus on autoimmune diseases and inflammatory conditions